Journal of Clinical Endocrinology & Metabolism, Vol 57, 488-495, Copyright © 1983 by Endocrine Society

ARTICLES

Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract

MA Ghatei, LO Uttenthal, ND Christofides, MG Bryant and SR Bloom

A means of estimating human enteroglucagon (glucagon-like immunoreactivity of intestinal origin) in tissues and plasma is described, based on the subtraction of RIA values obtained with the C- terminal-directed glucagon antiserum RCS5 from the total glucagon-like immunoreactivity determined with the N-terminal- to midmolecule- directed glucagon antiserum R59. Gel filtration on Sephadex G-50 of human plasma and extracts of normal human intestine separated the R59 immunoreactivity into three peaks: a small peak of void volume material, a major peak coeluting with porcine glicentin, and a smaller peak coeluting with pancreatic glucagon. No RCS5 immunoreactivity was detected in the human gut, except for a small amount constituting less than 2% of the total glucagon-like immunoreactivity in the ileum and rectum only. In extracts of human pancreas, the chromatographic profiles obtained with RCS5 and R59 assays differed from the intestinal patterns, but were identical to each other, giving no evidence of a significant amount of pancreatic R59 immunoreactivity that was not also reactive with RCS5. Chromatography of plasmas from healthy subjects and patients with dumping syndrome, active coeliac disease, and tropical sprue showed that only the second major peak of R59 immunoreactivity reflected the basal or postnutrient increases in the plasma enteroglucagon concentration. In patients with exaggerated enteroglucagon release, the rise was again found to be entirely due to an increase in this peak of immunoreactivity. This major molecular form of human enteroglucagon, similar in size to porcine glicentin, is, thus, the form most likely to be of physiological and pathophysiological significance.

This article has been cited by other articles:

				S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle The Obesity Epidemic: Pharmacological Challenges Mol. Interv., April 1, 2008; 8(2): 82 - 98. [Abstract] [Full Text] [PDF]

				E. T. Parlevliet, A. C. Heijboer, J. P. Schroder-van der Elst, L. M. Havekes, J. A. Romijn, H. Pijl, and E. P. M. Corssmit Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E142 - E147. [Abstract] [Full Text] [PDF]

				R. Burcelin, P. D. Cani, and C. Knauf Glucagon-Like Peptide-1 and Energy Homeostasis J. Nutr., November 1, 2007; 137(11): 2534S - 2538S. [Abstract] [Full Text] [PDF]

				N. M. Neary, C. J. Small, M. R. Druce, A. J. Park, S. M. Ellis, N. M. Semjonous, C. L. Dakin, K. Filipsson, F. Wang, A. S. Kent, et al. Peptide YY3-36 and Glucagon-Like Peptide-17-36 Inhibit Food Intake Additively Endocrinology, December 1, 2005; 146(12): 5120 - 5127. [Abstract] [Full Text] [PDF]

				S. Stanley, K. Wynne, B. McGowan, and S. Bloom Hormonal Regulation of Food Intake Physiol Rev, October 1, 2005; 85(4): 1131 - 1158. [Abstract] [Full Text] [PDF]

				K. Hussain, J. Bryan, H. T. Christesen, K. Brusgaard, and L. Aguilar-Bryan Serum Glucagon Counterregulatory Hormonal Response to Hypoglycemia Is Blunted in Congenital Hyperinsulinism Diabetes, October 1, 2005; 54(10): 2946 - 2951. [Abstract] [Full Text] [PDF]

				K. Wynne, A. J. Park, C. J. Small, M. Patterson, S. M. Ellis, K. G. Murphy, A. M. Wren, G. S. Frost, K. Meeran, M. A. Ghatei, et al. Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial Diabetes, August 1, 2005; 54(8): 2390 - 2395. [Abstract] [Full Text] [PDF]

				K. Wynne, S. Stanley, B. McGowan, and S. Bloom Appetite control J. Endocrinol., February 1, 2005; 184(2): 291 - 318. [Abstract] [Full Text] [PDF]

				C. L. Dakin, C. J. Small, R. L. Batterham, N. M. Neary, M. A. Cohen, M. Patterson, M. A. Ghatei, and S. R. Bloom Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats Endocrinology, June 1, 2004; 145(6): 2687 - 2695. [Abstract] [Full Text] [PDF]

				M. R. Druce, C. J. Small, and S. R. Bloom Minireview: Gut Peptides Regulating Satiety Endocrinology, June 1, 2004; 145(6): 2660 - 2665. [Abstract] [Full Text] [PDF]

				M. A. Cohen, S. M. Ellis, C. W. Le Roux, R. L. Batterham, A. Park, M. Patterson, G. S. Frost, M. A. Ghatei, and S. R. Bloom Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4696 - 4701. [Abstract] [Full Text] [PDF]

				M. Nian, J. Gu, D. M. Irwin, and D. J. Drucker Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R173 - R183. [Abstract] [Full Text] [PDF]

				C. M. B. Edwards, S. A. Stanley, R. Davis, A. E. Brynes, G. S. Frost, L. J. Seal, M. A. Ghatei, and S. R. Bloom Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E155 - E161. [Abstract] [Full Text] [PDF]